Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases.

ABSTRACT:

Background

In the INBUILD trial in patients with chronic fibrosing interstitial lung diseases (ILDs) and a progressive phenotype, nintedanib reduced the rate of ILD progression with adverse events that were manageable for most patients. We investigated the potential impact of immunomodulatory therapies on the efficacy and safety of nintedanib.

Methods

Subjects with fibrosing ILDs other than idiopathic pulmonary fibrosis, who had shown progression of ILD within the prior 24 months despite management in clinical practice, were randomized to receive nintedanib or placebo. Certain immunomodulatory therapies were restricted for the first 6 months. We analyzed post-hoc the rate of decline in forced vital capacity (FVC) over 52 weeks in subgroups by glucocorticoid use at baseline a

SUBMITTER: Cottin V 

PROVIDER: S-EPMC7962343 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature